Inosine pranobex in the treatment of mild cervical intraepithelial neoplasia (experience of clinical use)

Abstract

   Introduction. The article reflects the experience of treating patients with papillomavirus- associated lesion of the cervix – mild cervical intraepithelial neoplasia (CIN I) with the use of an immunostimulant with antiviral activity – inosine pranobex (tablets 500 mg) with an assessment of clinical and microbiological efficacy.   Aim. Evaluation of the effectiveness of immunomodulatory and antiviral therapy in patients with mild cervical intraepithelial neoplasia with a drug containing inosine pranobex.   Materials and methods. An analysis of treatment with a drug containing inosine pranobex (tablets 500 mg) of 78 women with CIN I (36 months of monitoring) was carried out. Methods: colposcopy, histological examination of biopsy specimens of cervical areas, Pap-test, PCR HPV (qualitative and quantitative), immunohistochemical (determination of markers p16ink4D, Ki-67).   Results. Presented experience of therapy with three-year monitoring of patients diagnosed with CIN I am using an oral immunostimulant with antiviral activity – inosine pranobex – (1000 mg 3 times a day for 28 days 1 time per year, showed its high clinical (84.2 %) and microbiological (83.3 %) efficacy with satisfactory tolerability of the drug.   Сonclusion. Immunotropic and nonspecific antiviral monotherapy with an oral inosine pranobex drug showed high clinical (recovery of colposcopic status – 83.3 %, cytohistologically confirmed absence of CIN in cervical scrapings – 85.9 %) and microbiological (PCR-negative HPV – 83.3 %) efficacy during the three-year monitoring.